On this page
3-M syndrome
Affected individuals typically experience significant growth delays before and after birth, alongside skeletal abnormalities and characteristic facial features. It is a rare inherited condition, meaning it is passed down through families.
Available at Jeen Health
Clinical tests that include this
Overview
3-M syndrome, sometimes referred to as Dolichospondylic Dysplasia, is a very rare genetic disorder characterised by distinctive physical features, most notably severe growth restriction occurring both before (prenatal) and after (postnatal) birth. This results in significantly short stature. Other common features include skeletal abnormalities, such as long slender bones and an unusually shaped spine, and specific facial characteristics [PMID:34289871].
The condition was originally named '3-M' after the surnames of the three doctors who first described it in 1975: Miller, McKusick, and Malvaux. Although rare, understanding 3-M syndrome enables early diagnosis and appropriate management strategies to support affected individuals. It is an inherited condition, meaning it runs in families and is passed down through specific genetic mechanisms.
Symptoms & clinical features
Individuals with 3-M syndrome typically present with a combination of clinical features. The most prominent symptom is marked short stature, which is noticeable from before birth and continues throughout childhood. Birth weight and length are usually significantly lower than average. Growth in infancy and childhood remains very slow, leading to adult height considerably below the population average [PMID:28795744].
Skeletal abnormalities are a key part of the condition. These often include slender long bones and changes in the shape of the vertebrae (bones of the spine), which can sometimes lead to a curved spine. Other features might involve shoulder blade abnormalities and limited elbow movement. Characteristic facial features can include a relatively large head circumference for the body size, a prominent forehead, a triangular face shape, large ears, and a short, broad neck. Some individuals may also have dental anomalies [PMID:34289871].
While intellectual development is typically unaffected in 3-M syndrome, some individuals may experience subtle developmental delays. The severity and combination of these symptoms can vary between affected individuals, even within the same family.
Video: Genetics 101
Affected organs
3-M syndrome primarily affects the skeletal system and growth processes throughout the body. The bones, particularly the long bones of the limbs and the vertebrae of the spine, show characteristic changes, including reduced density and specific shapes contributing to short stature. Muscles may also be affected, leading to a lean body build.
While the condition does not directly impact the function of internal organs like the heart, lungs, or brain, the overall growth restriction and skeletal features are systemic, meaning they affect the body broadly. The distinctive facial features are also a result of subtle alterations in bone and soft tissue development in the head and neck region.
Risks & severity
The severity of growth restriction in 3-M syndrome can be significant, often resulting in adult heights significantly below the average range. The condition is lifelong, and while the growth restriction is severe, it is not generally life-threatening. Individuals with 3-M syndrome typically have normal life expectancy.
Key risks relate to potential complications associated with skeletal abnormalities, such as spinal curvature or joint issues, which may require medical attention. There is generally no increased risk of specific cancers or other major medical conditions directly associated with 3-M syndrome. The exact prevalence of 3-M syndrome is not well established, but it is considered a very rare condition globally.
Genetic causes
3-M syndrome is caused by pathogenic variants in one of three genes: CUL7, OBSL1, or CCDC8. These genes provide instructions for making proteins that are all involved in the same cellular pathway, specifically regulating cell growth and division. When one of these genes has a pathogenic variant, the protein it produces may not function correctly, leading to disruptions in normal cell growth. This, in turn, affects overall body growth and development, leading to the characteristic features of 3-M syndrome [PMID:28795744].
The CUL7 gene plays a vital role in cellular quality control by marking unwanted proteins for destruction, influencing processes such as cell division and growth. OBSL1 and CCDC8 proteins interact with CUL7, forming a complex that is crucial for maintaining cellular functions essential for normal growth [PMID:28795744]. Pathogenic changes in any of these genes disrupt this complex, leading to the severe growth restriction seen in 3-M syndrome.
- CCDC8 coiled-coil domain containing 8 subunit of 3M complex
- CUL7 cullin 7The CUL7 gene provides instructions for producing the cullin-7 protein, a crucial component of the cellular machinery responsible for breaking down unwanted proteins and regulating growth processes.
- OBSL1 obscurin like cytoskeletal adaptor 1The OBSL1 gene provides instructions for a protein that is crucial in maintaining normal levels of cullin-7, a key component of the cell's protein degradation system.
Inheritance pattern
3-M syndrome is inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of the altered gene - one from each parent - to be affected by the condition. Individuals who inherit only one copy of the altered gene are known as carriers. Carriers typically do not show any symptoms of 3-M syndrome themselves.
If both parents are carriers of the same altered gene, there is a 25% (1 in 4) chance with each pregnancy that their child will inherit two altered copies and develop 3-M syndrome. There is a 50% (1 in 2) chance the child will be a carrier, and a 25% (1 in 4) chance the child will inherit two normal copies of the gene and will neither have the condition nor be a carrier. This inheritance pattern is important for family planning and genetic counselling.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of 3-M syndrome is typically considered based on characteristic clinical features, including severe pre- and postnatal growth restriction, specific skeletal abnormalities, and distinctive facial features. Imaging studies, such as X-rays, can help identify the skeletal changes often associated with the condition.
Genetic testing is used to confirm the diagnosis by identifying pathogenic variants in the CUL7, OBSL1, or CCDC8 genes. In the UK, genetic testing for suspected causes of severe short stature falls under the NHS Genomic Medicine Service. Referrals for genetic testing are typically made by a paediatrician or clinical geneticist after a thorough clinical assessment. Genetic counsellors can also provide support and information regarding testing options and results.
Management & lifestyle
Management of 3-M syndrome focuses on addressing the symptoms and supporting the overall well-being of affected individuals. While there is currently no cure for the underlying genetic cause, various interventions can help manage the condition.
Regular monitoring of growth and development by a paediatrician is essential. Physiotherapy may be recommended to address any skeletal or joint issues and to promote muscle strength and mobility. Orthopaedic interventions might be considered for significant spinal curvature or other specific bone problems. Dental care is also important due to potential dental anomalies. Growth hormone therapy generally shows limited effectiveness in increasing final adult height in 3-M syndrome, but its use can be discussed with specialists on a case-by-case basis. Individuals and families benefit from ongoing support from a multidisciplinary team, including clinical geneticists, paediatricians, and other specialists as needed.
UK care pathway
In the UK, individuals with suspected 3-M syndrome would typically enter the NHS Genomic Medicine Service pathway. Initial assessment often involves a paediatrician who may refer to a clinical geneticist for further evaluation. Genetic testing is performed via NHS Genomic Laboratory Hubs to confirm the diagnosis. Genetic counsellors are available to provide support, explain the inheritance pattern, and discuss implications for the family. Ongoing care involves multidisciplinary teams, often coordinated through specialist paediatric centres.
Frequently asked questions
Will a person with 3-M syndrome have a shorter life expectancy?
No, individuals with 3-M syndrome typically have a normal life expectancy. The condition primarily affects growth and skeletal development, but it is not usually associated with life-limiting health complications.
Is intellectual development affected in 3-M syndrome?
Generally, intellectual development is not affected in individuals with 3-M syndrome. Most people with the condition have typical cognitive abilities, although some might experience subtle developmental delays.
Can growth hormone treatment help with 3-M syndrome?
Growth hormone therapy typically has limited effectiveness in significantly increasing the adult height of individuals with 3-M syndrome. However, its potential use should be discussed with an endocrinologist or paediatric growth specialist.
If I have 3-M syndrome, what are the chances my children will have it?
3-M syndrome is inherited in an autosomal recessive pattern. This means if you have the condition, you would pass on one altered copy of the gene to each of your children. Whether your children also have the condition depends on whether your partner is a carrier of an altered gene. If your partner is not a carrier, your children will be carriers but will not have the condition. Genetic counselling can provide personalised risk assessments.
What kind of doctors treat 3-M syndrome?
Management of 3-M syndrome often involves a team of specialists, including paediatricians, clinical geneticists, orthopaedic surgeons (for bone issues), physiotherapists, and potentially endocrinologists (for growth concerns). Dental specialists may also be involved for specific dental needs.
References
- Adam MP, Bick S, Mirzaa GM. 3-M Syndrome. 1993. PMID: 20301654
- Karacan Küçükali G, Keskin M, Aycan Z. 3M syndrome: Evaluating the clinical and laboratory features and the response of the growth hormone treatment: Single center experience. European journal of medical genetics. 2023. PMID: 37673300
- Huang Y, Liu C, Ding H. Exome sequencing in fetuses with short long bones detected by ultrasonography: A retrospective cohort study. Frontiers in genetics. 2023. PMID: 36923788
- Flannery DB. 3-M syndrome. American journal of medical genetics. 1989. PMID: 2929663
- HabibUllah H, Al-Baradie R, Bashir S. 3-M Syndrome: A Local Case Report. The American journal of case reports. 2019. PMID: 30622233
- Lugli L, Bertucci E, Mazza V. Pre- and post-natal growth in two sisters with 3-M syndrome. European journal of medical genetics. 2016. PMID: 26850509
- Ozturk AP, Aslanger AD, Altunoglu U. Long-term follow-up of growth and puberty in 3-M syndrome: effects of growth hormone therapy and response variability. Endocrine. 2025. PMID: 40974508
- Bacchi I, Vandelli S, Coccia E. 3-M syndrome: evolution of the phenotype over time. Italian journal of pediatrics. 2025. PMID: 41437277